Adult Immunization
Hepatology
Pediatric Immunization
Screening
Psychiatry
Allergy
Women's Health
Cardiology
Pediatrics
Dermatology
Endocrinology
Pain Management
Gastroenterology
Geriatrics
Infectious Disease
Obesity Medicine
Rheumatology
Oncology
Nephrology
Neurology
Pulmonology

Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause Early Identification of Alzheimer's Disease Adult Immunization Center Dermatology Hot Topics

Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from Pediatric Endocrinology of North Texas : Episode 2

T1D Staging: The Clinical Importance of Early Recognition

August 2, 2024

Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP
Amy Burton, MD

Opinion

Video

The panel outlines the stages of type 1 diabetes, focusing on the importance of early intervention to prevent complications of the disease.

EP: 1.Navigating T1D: Mitigating Burden and Monitoring Disease Progression

EP: 2.T1D Staging: The Clinical Importance of Early Recognition

EP: 3.Engaging the Audience: Polling on Primary Populations and Community Perspectives in T1D Care

EP: 4.T1D Antibody Screening: Identifying High-Risk Populations

EP: 5.Role of Teplizumab: First Approved Treatment for Delaying T1D Stage Progression

EP: 6.TN-10 Study Analysis: Expert Perspectives on Key Efficacy and Safety Data

EP: 7.Exploring Screening and Real-World Use of Teplizumab: Practical Insights and Clinical Experiences

EP: 8.Teplizumab Infusion Protocol: Details on the 14-Day Process and Comprehensive Monitoring Overview

EP: 9.Expert Opinions into the Range of Teplizumab Infusion Locations, Insurance Coverage Hurdles, and the Approval Process

EP: 10.Final Thoughts on Strategies for Managing and Monitoring Patients Receiving Teplizumab

Related Videos

New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time

Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik

Related Content

Breast Cancer Screening: A Conversation with Mette Kalager, MD

Breast Cancer Screening: A Conversation with Mette Kalager, MD

Mette Kalager, MD, PhD;Sydney Jennings

April 21st 2025

ACP 2025: Dr Kalager shares strategies for addressing patient beliefs, presenting risk data, and promoting shared decision-making in primary care settings.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Patient Navigation Program Improves Colonoscopy Completion Rates After Abnormal FIT Results / Image credit University of Arizona Cancer Center

Patient Navigation Program Improves Colonoscopy Completion Rates After Abnormal FIT Results

April 18th 2025

The phone-based patient navigation intervention addressed barriers to CRC testing follow-up and included patient education.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Novel Non-Invasive Glucose Monitor Uses Light-Based Technology / image credit RSP Systems

Novel Non-Invasive Glucose Monitor Uses Light-Based Technology

April 11th 2025

Accuracy of data recorded with the GlucoBeam was found to be comparable to standard finger-stick blood glucose tests.

Dexcom G7 15 Day CGM System Cleared by FDA / image credit ©Waldenmarus/stock.adobe.com

Dexcom G7 15 Day CGM System Cleared by FDA

April 10th 2025

The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%

Related Content

Breast Cancer Screening: A Conversation with Mette Kalager, MD

Breast Cancer Screening: A Conversation with Mette Kalager, MD

Mette Kalager, MD, PhD;Sydney Jennings

April 21st 2025

ACP 2025: Dr Kalager shares strategies for addressing patient beliefs, presenting risk data, and promoting shared decision-making in primary care settings.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Patient Navigation Program Improves Colonoscopy Completion Rates After Abnormal FIT Results / Image credit University of Arizona Cancer Center

Patient Navigation Program Improves Colonoscopy Completion Rates After Abnormal FIT Results

April 18th 2025

The phone-based patient navigation intervention addressed barriers to CRC testing follow-up and included patient education.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Novel Non-Invasive Glucose Monitor Uses Light-Based Technology / image credit RSP Systems

Novel Non-Invasive Glucose Monitor Uses Light-Based Technology

April 11th 2025

Accuracy of data recorded with the GlucoBeam was found to be comparable to standard finger-stick blood glucose tests.

Dexcom G7 15 Day CGM System Cleared by FDA / image credit ©Waldenmarus/stock.adobe.com

Dexcom G7 15 Day CGM System Cleared by FDA

April 10th 2025

The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%

Editorial Board

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.